…

The choice of chitosan as the delivery vehicle for this experimental vaccine reflects a growing body of research into biopolymer-based nanocarriers for mucosal immunization. Chitosan, derived from chitin found in crustacean shells, is positively charged at physiological pH, which allows it to form stable complexes with negatively charged bacterial membrane components and mucosal surfaces. This electrostatic attraction underlies the mucoadhesive properties that help nanoparticles linger in the intestinal lumen long enough for immune cells sampling the gut lumen to capture the enclosed antigens. The mannose conjugation described in the study adds a second layer of targeting: mannose receptors are abundantly expressed on dendritic cells and macrophages within gut-associated lymphoid tissues, so decorating the nanoparticle surface with mannose residues effectively directs the antigen payload to the very cells responsible for initiating adaptive immune responses. The reported particle size of roughly 286 nanometers falls within a range generally considered favorable for uptake by M cells, the specialized epithelial cells that ferry luminal material to underlying lymphoid tissue, while the positive zeta potential of about 34.6 millivolts suggests colloidal stability, since particles with similar charges repel one another and resist aggregation during storage and passage through the digestive tract.

The antigen selection in this nanovaccine also merits attention. Outer membrane proteins of Salmonella are surface-exposed and participate in host cell attachment and immune recognition, making them logical targets for antibodies that can interfere with the earliest steps of infection. Flagella antigens, meanwhile, are not merely structural components; flagellin, the monomeric building block of the bacterial flagellum, is recognized by innate immune receptors such as Toll-like receptor 5, which means that including flagellar material in a vaccine can simultaneously provide a protective antigen target and a built-in innate immune stimulus. Combining these two antigen classes in a single particle therefore offers both specificity and immunostimulatory potential, a design philosophy that contrasts with older subunit approaches relying on single purified proteins.

The timing of probiotic administration in this study is noteworthy from a developmental immunology perspective. In ovo delivery at embryonic day 18 means that Lactobacillus acidophilus is introduced just before hatching, a period when the chick’s gut is essentially sterile and the immune system is beginning to encounter the microbial world. Research on early-life microbial colonization has shown that the first microbial residents of the intestine can have lasting effects on immune system calibration, influencing the balance between inflammatory and regulatory responses for weeks afterward. By seeding the gut with a beneficial organism before the chick ever encounters environmental microbes, feed, or pathogens, the researchers aimed to establish a gut environment primed for mucosal immunity. The subsequent post-hatch doses at days 2, 4, and 6 reinforce this early colonization during the window when the intestinal epithelium and immune tissues are still maturing rapidly.

The immunological findings reported in the study align with established principles of mucosal vaccine design. Secretory IgA is the dominant antibody class at mucosal surfaces, where it functions by agglutinating bacteria, blocking their attachment to epithelial cells, and neutralizing toxins without triggering the inflammatory consequences associated with complement activation. The observation that the probiotic-nanovaccine combination increased specific secretory IgA in both the intestine and bile is significant because bile IgA reflects immune activity in the upper intestinal tract and liver-associated lymphoid tissues, providing a broader measure of mucosal immunity than intestinal secretions alone. The elevation of activated B cells suggests that the vaccine successfully engaged the germinal center reactions and T cell help needed to drive antibody class switching toward the IgA isotype, a process heavily influenced by the cytokine milieu in gut lymphoid tissues.

The cytokine profile observed in the cecal tonsils provides additional insight into the quality of the immune response generated. Interferon-gamma, a hallmark Th1 cytokine, promotes cell-mediated immunity and macrophage activation, both of which are important for controlling intracellular pathogens like Salmonella that can survive within host cells. Interleukin-17, produced by Th17 cells, recruits neutrophils and stimulates epithelial cells to produce antimicrobial peptides, strengthening the barrier function of the intestinal lining. The concurrent detection of interleukin-10, an anti-inflammatory cytokine, suggests that the immune response was not skewed toward uncontrolled inflammation but rather achieved a balance between pathogen clearance and tissue preservation. This balance is particularly relevant in the intestine, where excessive inflammation can damage the epithelial barrier and paradoxically facilitate bacterial translocation.

The microbiome data add an important dimension to the interpretation of vaccine efficacy. The finding that overall microbial diversity was not altered by the probiotic-nanovaccine combination is reassuring from an ecological standpoint, since dramatic disruptions of the gut microbiome can have unintended consequences for digestion, nutrient absorption, and pathogen resistance. However, the significant shift in community composition, with an R-squared value of 0.378, indicates that the treatment did meaningfully restructure which taxa were present and in what relative abundances. The enrichment of short-chain fatty acid-producing Clostridiales, including genera such as Blautia, Butyricicoccus, and members of the Christensenellaceae family, is consistent with a beneficial shift, as these organisms produce metabolites that nourish colonocytes, strengthen epithelial tight junctions, and modulate immune cell function. Short-chain fatty acids such as butyrate and acetate have been shown to promote regulatory T cell development and to create an intestinal environment less hospitable to facultative anaerobes like Salmonella.

By contrast, the commercial live-attenuated vaccine group showed an increase in Escherichia and Shigella alongside a reduction in Lactobacillus, a pattern that could reflect either direct effects of the live vaccine strain on the gut ecosystem or indirect consequences of the inflammatory environment it generates. Live-attenuated Salmonella vaccines replicate within the host and can transiently perturb the intestinal microbiota, potentially opening ecological niches that opportunistic organisms can fill. This distinction between the two vaccination strategies highlights a potential advantage of subunit nanovaccines combined with probiotics: they can confer protection without the ecological side effects associated with administering a replicating organism.

The reduction in cecal Salmonella Enteritidis colonization by 1.2 log10 units compared with the commercial vaccine represents a meaningful improvement in pathogen burden. In practical terms, each log10 reduction corresponds to a tenfold decrease in bacterial numbers, so a 1.2 log10 reduction means roughly a sixteenfold lower bacterial load in the cecum. Because the cecum is the primary reservoir for Salmonella in poultry and the source of fecal contamination that spreads the organism through flocks and onto carcasses during processing, reducing cecal colonization directly translates to lower contamination of meat products and, by extension, reduced risk to consumers. The measurement at four days post-challenge captures the peak of the acute colonization phase, when differences between vaccinated and unvaccinated birds are most pronounced.

The broader context of this work relates to ongoing efforts to reduce antimicrobial use in food animal production. As regulatory pressure and consumer demand drive the poultry industry away from routine antibiotic administration, alternative strategies for maintaining flock health and food safety have become increasingly urgent. Probiotics, prebiotics, organic acids, bacteriophages, and vaccines each play a role in this transition, but their combined application, as demonstrated in this study, may offer synergistic benefits that no single intervention can achieve alone. The concept of using a probiotic as a vaccine adjuvant rather than as a standalone intervention represents a refinement of both approaches, leveraging the immunomodulatory capacity of Lactobacillus acidophilus to amplify the response to a defined antigen payload delivered via nanoparticles.

Questions remain regarding the scalability and field applicability of this approach. In ovo vaccination requires specialized equipment and trained personnel, though it is already widely practiced in commercial hatcheries for other vaccines such as Marek’s disease, suggesting that the logistical infrastructure exists. The stability of chitosan nanoparticles under commercial storage and transport conditions, the cost of producing antigen-loaded particles at industrial scale, and the consistency of probiotic colonization across different genetic lines of broilers are all factors that would need to be addressed before this technology could move from the laboratory to the hatchery floor. Additionally, the study focused on Salmonella Enteritidis, and further research would be needed to determine whether the same platform provides cross-protection against other Salmonella serovars that circulate in poultry flocks, such as Salmonella Typhimurium or Salmonella Heidelberg.

The regulatory landscape for such combination products also warrants consideration. A product combining a live probiotic organism with a nanoparticle-encapsulated subunit vaccine may fall under multiple regulatory frameworks, and establishing safety and efficacy data sufficient for approval would require additional studies in larger numbers of birds across multiple farms and production cycles. Nevertheless, the conceptual framework demonstrated here, namely that probiotic priming of the gut can enhance the immunogenicity of an oral nanovaccine while simultaneously shaping the microbiome in ways that favor pathogen resistance, offers a template for future interventions targeting not only Salmonella but also other enteric pathogens of poultry, including Campylobacter, Clostridium perfringens, and pathogenic Escherichia coli. The integration of nanotechnology, probiotics, and mucosal immunology in a single intervention strategy reflects the multidisciplinary direction that veterinary vaccine research is increasingly taking as the industry seeks alternatives to antimicrobial growth promotion and responds to consumer expectations regarding food safety and animal welfare.

Subject of Research: Probiotic Lactobacillus acidophilus provides an adjuvant effect to an orally administered chitosan nanoparticle-based Salmonella subunit vaccine in broilers against Salmonella Enteritidis infection

Article Title: Probiotic Lactobacillus acidophilus provides an adjuvant effect to an orally administered chitosan nanoparticle-based Salmonella subunit vaccine in broilers against Salmonella Enteritidis infection

Article References: Dolatyabi, S., Sharma, S., Olaitan Shekoni, C., Suresh, R., Yadav, S., Schrock, J., Wood, R., Shivalingaiah, G. A., Dhakal, A., Tenney, M., Rahman, T., Sanko, J., Lagos, R. Z., Abdelaziz, K., & Renukaradhya, G. J. (2026). Probiotic Lactobacillus acidophilus provides an adjuvant effect to an orally administered chitosan nanoparticle-based Salmonella subunit vaccine in broilers against Salmonella Enteritidis infection. Frontiers in Microbiology, 17, Article 1898587. https://doi.org/10.3389/fmicb.2026.1898587

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1898587

Keywords: Probiotic, Lactobacillus, acidophilus, provides, adjuvant, effect, orally, administered, chitosan, nanoparticle-based, Salmonella, subunit